Prelude Therapeutics Incorporated (PRLD)
Recent FMP quote capitalization/price differs materially from the dedicated count; unresolved share-class or unit scope prevents a current headline. Weighted-average statement values below are not a substitute for a current share count.
FMP supplied 78,497,652 shares, with feed update 2026-10-06 06:18:20 (timezone and share-count effective date not supplied). This observation is withheld from the headline while its security scope is unresolved.
Comparison quote: 2026-10-06T18:55:11.000Z. The implied count is used only to flag conflicts; it does not replace the source count.
Shares outstanding measure the share count in the provider observation. Basic and diluted weighted averages below are EPS calculation inputs. Differences between these counts do not measure new issuance or buybacks.
FMP normalized EPS denominators, labeled by statement period end. These are weighted averages, not current shares outstanding. The provider's period duration may include year-to-date values. Q2 FY2026 (2026-06-30): 98.39M.
FMP normalized EPS denominators, labeled by statement period end. These are weighted averages, not current shares outstanding. The provider's period duration may include year-to-date values. Q2 FY2026 (2026-06-30): 98.39M.
FMP normalized EPS denominators, labeled by statement period end. These are weighted averages, not current shares outstanding. The provider's period duration may include year-to-date values.
| Statement period | Period end | Weighted average basic shares | Weighted average diluted shares |
|---|---|---|---|
| Q2 FY2026 | 2026-06-30 | 98,388,593 | 98,388,593 |
| Q1 FY2026 | 2026-03-31 | 82,519,981 | 82,519,981 |
| Q4 FY2025 | 2025-12-31 | 62,953,628 | 62,953,628 |
| Q3 FY2025 | 2025-09-30 | 76,132,337 | 76,132,337 |
| Q2 FY2025 | 2025-06-30 | 75,993,941 | 75,993,941 |
| Q1 FY2025 | 2025-03-31 | 75,986,281 | 75,986,281 |
| Q4 FY2024 | 2024-12-31 | 75,896,061 | 75,896,061 |
| Q3 FY2024 | 2024-09-30 | 75,855,949 | 75,855,949 |
| Q2 FY2024 | 2024-06-30 |
FMP normalized EPS denominators, labeled by statement period end. These are weighted averages, not current shares outstanding. The provider's period duration may include year-to-date values.
| Statement period | Period end | Weighted average basic shares | Weighted average diluted shares |
|---|---|---|---|
| 2025 | 2025-12-31 | 76,956,194 | 76,956,194 |
| 2024 | 2024-12-31 | 75,805,840 | 75,805,840 |
| 2023 | 2023-12-31 | 60,357,000 | 60,357,052 |
| 2022 | 2022-12-31 | 47,371,589 | 47,371,589 |
| 2021 | 2021-12-31 | 47,602,336 | 47,602,336 |
| 2020 | 2020-12-31 | 43,705,672 | 43,705,672 |
| 2019 | 2019-12-31 | 32,401,826 | 32,401,826 |
| 2018 | 2018-12-31 | 1,576,000 | 1,576,395 |
| 75,762,152 |
| 75,762,152 |
| Q1 FY2024 | 2024-03-31 | 75,735,954 | 75,735,954 |
| Q4 FY2023 | 2023-12-31 | 69,591,000 | 69,591,823 |
| Q3 FY2023 | 2023-09-30 | 67,639,993 | 67,639,993 |
| Q2 FY2023 | 2023-06-30 | 56,240,000 | 56,240,491 |
| Q1 FY2023 | 2023-03-31 | 47,737,190 | 47,737,190 |
| Q4 FY2022 | 2022-12-31 | 47,899,031 | 47,899,031 |
| Q3 FY2022 | 2022-09-30 | 47,449,811 | 47,449,811 |
| Q2 FY2022 | 2022-06-30 | 47,276,684 | 47,276,684 |
| Q1 FY2022 | 2022-03-31 | 47,066,427 | 47,066,427 |
| Q4 FY2021 | 2021-12-31 | 46,330,794 | 46,330,794 |
| Q3 FY2021 | 2021-09-30 | 46,330,794 | 46,330,794 |
| Q2 FY2021 | 2021-06-30 | 46,057,112 | 46,057,112 |
| Q1 FY2021 | 2021-03-31 | 45,121,955 | 45,121,955 |
| Q4 FY2020 | 2020-12-31 | 38,053,749 | 38,053,749 |
| Q3 FY2020 | 2020-09-30 | 38,053,749 | 38,053,749 |
| Q2 FY2020 | 2020-06-30 | 38,053,749 | 38,053,749 |
| Q1 FY2020 | 2020-03-31 | 32,401,826 | 32,401,826 |
| Q4 FY2019 | 2019-12-31 | 32,401,826 | 32,401,826 |
| Q3 FY2019 | 2019-09-30 | 32,401,826 | 32,401,826 |
| Q2 FY2019 | 2019-06-30 | 1,576,000 | 1,576,395 |
| Q1 FY2019 | 2019-03-31 | 1,576,000 | 1,576,395 |
